Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.42 |
| ▸ | HTR2A | P28223 | 9/20 | 0.40 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927854 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BFABP4HTR6 | |
| SCHEMBL29780344 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BFABP4HTR6 | |
| SCHEMBL7997702 | 0.82 | HTR2C (0.61) | HTR2CHTR2AHTR2B | |
| SCHEMBL23927940 | 0.81 | HTR2C (0.44) | HTR2CHTR2AALDH1A1LMNA | |
| SCHEMBL29780347 | 0.81 | HTR2C (0.44) | HTR2CHTR2AALDH1A1LMNA | |
| SCHEMBL23927941 | 0.81 | HTR2C (0.44) | HTR2CHTR2AALDH1A1LMNA | |
| SCHEMBL23927911 | 0.79 | HTR2C (0.54) | HTR2CHTR2AHTR6ALDH1A1HTR1A | |
| SCHEMBL23927920 | 0.77 | HTR2C (0.70) | HTR2CHTR2AHTR2BFABP4HTR6 | |
| SCHEMBL23927922 | 0.77 | HTR2C (0.70) | HTR2CHTR2AHTR2BFABP4HTR6 | |
| SCHEMBL18247631 | 0.77 | CYP19A1 (0.43) | HTR2CHTR2AFABP4CNR2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | HTR2C 3/4885HTR2A 5/4885HTR2B 11/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | HTR2C 3/4885HTR2A 5/4885HTR2B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.